Literature DB >> 26739481

Mechanisms for the Specific Properties of γ-Hydroxybutyrate in Brain.

Michel Maitre1, Christian Klein1, Ayikoe G Mensah-Nyagan1.   

Abstract

γ-Hydroxybutyrate (GHB) is both a natural brain compound with neuromodulatory properties at central GABAergic synapses (micromolar concentration range) and also a drug (Xyrem(R) ) clinically used for the treatment of various neurological symptoms (millimolar dose range). However, this drug has abuse potential and can be addictive for some patients. Here, we review the basic mechanistic role of endogenous GHB in brain as well as the properties and mechanisms of action for therapeutic clinical doses of exogenous GHB. Several hypotheses are discussed with a preference for a molecular mechanism that conciliates most of the findings available. This conciliatory model may help for the design of GHB-like drugs active at lower doses and devoid of major side effects.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  GHB; gamma-hydroxybutyrate; mechanisms of action; therapeutic doses; xyrem

Mesh:

Substances:

Year:  2016        PMID: 26739481     DOI: 10.1002/med.21382

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  15 in total

1.  Gamma-Hydroxybutyrate (GHB) Content in Hair Samples Correlates Negatively with Age in Succinic Semialdehyde Dehydrogenase Deficiency.

Authors:  S S Johansen; X Wang; D Sejer Pedersen; P L Pearl; J-B Roullet; G R Ainslie; K R Vogel; K M Gibson
Journal:  JIMD Rep       Date:  2017-02-18

2.  Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder.

Authors:  K R Vogel; G R Ainslie; A McConnell; J-B Roullet; K M Gibson
Journal:  Toxicol In Vitro       Date:  2017-10-12       Impact factor: 3.500

3.  Shallow metabolic depression and human spaceflight: a feasible first step.

Authors:  Matthew D Regan; Erin E Flynn-Evans; Yuri V Griko; Thomas S Kilduff; Jon C Rittenberger; Keith J Ruskin; C Loren Buck
Journal:  J Appl Physiol (1985)       Date:  2020-01-30

4.  Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Authors:  K R Vogel; G R Ainslie; E E W Jansen; G S Salomons; K M Gibson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-17       Impact factor: 5.187

5.  Correlation of blood biomarkers with age informs pathomechanisms in succinic semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Authors:  E E Jansen; K R Vogel; G S Salomons; P L Pearl; J-B Roullet; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2016-09-29       Impact factor: 4.982

6.  mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Authors:  Kara R Vogel; Garrett R Ainslie; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2016-08-12       Impact factor: 4.982

Review 7.  Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Authors:  P Malaspina; J-B Roullet; P L Pearl; G R Ainslie; K R Vogel; K M Gibson
Journal:  Neurochem Int       Date:  2016-06-14       Impact factor: 3.921

Review 8.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009

9.  Diversity and Evolutionary Analysis of Iron-Containing (Type-III) Alcohol Dehydrogenases in Eukaryotes.

Authors:  Carlos Gaona-López; Adriana Julián-Sánchez; Héctor Riveros-Rosas
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

Review 10.  A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer's disease.

Authors:  Michel Maitre; Christian Klein; Ayikoe G Mensah-Nyagan
Journal:  Alzheimers Res Ther       Date:  2016-09-06       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.